Literature DB >> 11319908

Functional correction of fanconi anemia group C hematopoietic cells by the use of a novel lentiviral vector.

K Yamada1, J C Olsen, M Patel, K W Rao, C E Walsh.   

Abstract

Lentiviral vectors transduce nondividing hematopoietic cells more efficiently than other currently available vector systems. Here we report the results of human hematopoietic cell gene transfer using lentiviral vectors based upon human immunodeficiency virus (HIV-1) and equine infectious anemia virus (EIAV). EIAV is a nonprimate lentivirus and is severely restricted in its host range to horses and closely related equines. We employed the EIAV vector system to test for gene transfer to human Fanconi anemia (FA) hematopoietic cells by comparison with HIV-1- and Moloney murine leukemia virus-based systems. Fanconi anemia is characterized by bone marrow failure secondary to stem cell dysfunction. Fanconi anemia group C EBV-transformed lymphoblasts were transduced with all three viral vectors. Phenotypic correction of FA cells, as measured by mitomycin C drug resistance, was observed with a similar efficiency in all vector systems. This is the first description of lentiviral correction of FA cells and suggests that lentiviral vectors may be useful for FA gene transfer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11319908     DOI: 10.1006/mthe.2001.0287

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  7 in total

Review 1.  Gene delivery into primary T cells: overview and characterization of a transgenic model for efficient adenoviral transduction.

Authors:  Vincent Hurez; Robin D Hautton; James Oliver; R James Matthews; Casey K Weaver
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  Comparison of gene transfer efficiencies and gene expression levels achieved with equine infectious anemia virus- and human immunodeficiency virus type 1-derived lentivirus vectors.

Authors:  J P O'Rourke; G C Newbound; D B Kohn; J C Olsen; B A Bunnell
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

3.  Insights into neurogenesis and aging: potential therapy for degenerative disease?

Authors:  Robert A Marr; Rosanne M Thomas; Daniel A Peterson
Journal:  Future Neurol       Date:  2010-07-01

4.  Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector.

Authors:  P S Becker; J A Taylor; G D Trobridge; X Zhao; B C Beard; S Chien; J Adair; D B Kohn; J E Wagner; A Shimamura; H-P Kiem
Journal:  Gene Ther       Date:  2010-05-20       Impact factor: 5.250

5.  In vivo repopulation ability of genetically corrected bone marrow cells from Fanconi anemia patients.

Authors:  Odile Cohen-Haguenauer; Bruno Péault; Cécile Bauche; Marie-Thérèse Daniel; Ibrahim Casal; Vincent Levy; Jean Dausset; Michel Boiron; Christian Auclair; Eliane Gluckman; Michel Marty
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-06       Impact factor: 11.205

Review 6.  The Fanconi anemia pathway and ubiquitin.

Authors:  Céline Jacquemont; Toshiyasu Taniguchi
Journal:  BMC Biochem       Date:  2007-11-22       Impact factor: 4.059

Review 7.  Gene Therapy Applications of Non-Human Lentiviral Vectors.

Authors:  Altar M Munis
Journal:  Viruses       Date:  2020-09-29       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.